ADAPTIVE BIOTECHNOLOGIES CORPORATION Restructuring Costs
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Restructuring Costs of $9.20 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2026-02-26
- ADAPTIVE BIOTECHNOLOGIES CORPORATION restructuring costs for the quarter ending 2024-12-31 was $100.00K.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION restructuring costs for the quarter ending 2024-09-30 was $200.00K.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION restructuring costs for the quarter ending 2024-06-30 was $7.90M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION restructuring costs for the quarter ending 2024-03-31 was $1.00M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION restructuring costs for fiscal 2024 was $9.20M.
| Period end | Restructuring Costs 3 month | Restructuring Costs 6 month | Restructuring Costs 9 month | Restructuring Costs 12 month |
|---|---|---|---|---|
| 2024-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $300.00K derived: sum of 2 quarters · filed 2026-02-26 | $8.20M derived: sum of 3 quarters · filed 2026-02-26 | $9.20M 10-K · filed 2026-02-26 |
| 2024-09-30 | $200.00K 10-Q · filed 2025-11-05 | $8.10M derived: sum of 2 quarters · filed 2025-11-05 | $9.10M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $7.90M derived: 10-Q 6 month − 10-K 3 month · filed 2025-08-05 | $8.90M 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | $1.00M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |